MedTrace Logo

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

NCT02445976 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2019-02-01

No results posted yet for this study

Summary

The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with enzalutamide and/or abiraterone.

Conditions

Interventions

DRUG

Seviteronel: given orally once daily in 28-day cycles

Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose

Sponsors & Collaborators

  • Prostate Cancer Foundation

    collaborator OTHER

  • Prostate Cancer Clinical Trials Consortium

    collaborator OTHER

  • Innocrin Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-12-31
Completion
2019-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02445976 on ClinicalTrials.gov